# EDGAR Filing Document

**Accession Number:** 0001677940
**File Stem:** 0001171843-25-007217
**Filing Date:** 2025-11
**Character Count:** 22051
**Document Hash:** 17ea2b029ecbd3ffd72f3fc6d87ea01d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-007217.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001171843-25-007217

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BeyondSpring Inc.
- **CENTRAL INDEX KEY:** 0001677940
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38024
- **FILM NUMBER:** 251468636

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** 646-528-4184

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR
- **STREET 2:** SUITE 410
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

?xml version='1.0' encoding='ASCII'? Form 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

### Washington, D.C. 20549
_________________

### FORM 8-K
_________________

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): November 12, 2025
_______________________________

#### BeyondSpring Inc.
(Exact name of registrant as specified in its charter)

_______________________________

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-38024** | **Not Applicable** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

#### 100 Campus Drive, West Side, 4th Floor, Suite 410

#### Florham Park, New Jersey 07932
(Address of Principal Executive Offices) (Zip Code)

#### +1 (646) 305-6387
(Registrant's telephone number, including area code)

#### Not Applicable
(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Ordinary Shares, par value $0.0001 per share | BYSI | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On November 12, 2025, BeyondSpring Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.** 

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit</u>** |
| [99.1](exh_991.htm) | [Press release, dated November 12, 2025.](exh_991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BeyondSpring Inc.** | **BeyondSpring Inc.** |
| Date: November 12, 2025 | By: | <u>/s/ Lan Huang&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Lan Huang |
|  |  | Chairperson and Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update**

* Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. 

* SEED, co-founded by BeyondSpring with 38% equity share, successfully completed its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39.

* SEED Named Finalist for 2025 Prix Galien USA "Best Start-Up" Award

FLORHAM PARK, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- **BeyondSpring Inc.** (NASDAQ: BYSI), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today reported Q3 2025 financial results alongside clinical and corporate milestones.

"With over 700 patients treated, Plinabulin continues to demonstrate a favorable safety profile and meaningful potential as an immune-modulating therapy with unique mechanism of dendritic cell (DC) maturation and T cell priming," said Dr. Lan Huang, Co-Founder, Chair and Chief Executive Officer of BeyondSpring. "With DC bridging innate and adaptive immunity, Plinabulin offers new hope for patients with NSCLC and other cancers whose disease progresses after checkpoint inhibitors, presented at recent SITC conference. In addition, results from our global Phase 3 DUBLIN-3 trial, published in *The Lancet Respiratory Medicine*, showed that Plinabulin in combination with docetaxel achieved durable survival benefits and reduced chemotherapy-induced neutropenia, reinforcing its potential to advance the standard of care and drive long-term value creation."

Dr. Huang added, "At SEED, which we co-founded with Lilly five years ago, we are excited that our RBM39 molecular-glue degrader has received IND clearance from both the US FDA and China NMPA. It is such an honor to be the only target protein degradation company nominated by the Prix Galien Foundation, recognizing our commitment to developing transformative medicine for patients. We are also grateful for the support of our investors and collaborators, including Lilly and Eisai, and clinicians from leading US institutions, as we work together to advance molecular glue development to address undruggable targets for patients with unmet medical needs."

**Key Milestones:** 

* **Two SITC 2025 Presentations on Plinabulin Anti-cancer Clinical Benefit:** **Resensitize NSCLC Patients Who Progressed on Prior PD-1/L1 Inhibitors with Disease Control Rate of 85% in Phase 2 Clinical Study**: New data from a phase 2 investigator-initiated study (NCT05599789, Peking Union Hospital China) evaluating Plinabulin, docetaxel, and pembrolizumab in metastatic NSCLC patients who progressed on prior PD-1/L1 inhibitors (n=47), showed encouraging efficacy and safety data. The combination demonstrated median progression-free survival (PFS) of 7.0 months, confirmed objective response rate (ORR) of 18.2%, duration of response (DOR) of 7.2 months, disease control rate (DCR) of 85%, and 12-month overall survival (OS) rate at 79%, and 24-month OS rate at 66% (median OS not reached).**Resensitize Patients with Eight Cancer Types Who Failed Prior PD-1/L1 Inhibitors with Disease Control Rate of 54% through DC Maturation and M1 Macrophage Polarization via GEF-H1-dependent Mechanism in Phase 1 Clinical Study:** This phase 1 investigator-initiated study (NCT04902040, MD Anderdon Cancer Center) shows that in addition to potent DC maturation for a systemic immune response, plinabulin combined with radiation and PD-1 inhibitor promotes proinflammatory monocytes and M1 macrophage polarization via a Plinabulin specific GEF-H1-dependent mechanism with the potential of overcoming acquired resistance to immune checkpoint inhibitors from pro-tumor macrophages. 

* **SEED, Co-founded by BeyondSpring with 38% Equity Share, Secured Financial Position and Achieved IND Clearance**: SEED completed its $30 million Series A-3 financing and received U.S. FDA and China NMPA clearance of its Investigational New Drug (IND) application for its lead RBM39 degrader program. SEED was also named a finalist for the 2025 Prix Galien USA "Best Start-Up" Award and co-hosted a targeted protein degradation symposium at NYU Grossman School of Medicine honoring Co-Founder and Nobel Laureate Prof. Avram Hershko, with leading thought leaders in the TPD field as presenters.

**Third Quarter Financial Results<sup>1</sup>**

Continuing operations:

* Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024. The $0.4 million increase was primarily due to higher drug manufacturing expenses, higher professional service expenses in regulatory affairs and higher volume of Plinabulin combination therapy research to support strategic business development and partnership initiatives.

* General and administrative (G&A) expenses were $0.8 million for the quarter ending September 30, 2025 compared to $1.7 million for the quarter ended September 30, 2024. The $0.9 million decrease was primarily due to lower professional service costs in consulting for business development and partnership initiatives, and lower salary expenses driven by decrease in administrative headcount.

* Net loss: $1.7 million for the quarter ended September 2025, compared to $2.2 million for the quarter ended September 2024

* Cash and cash equivalents: $12.5 million as of September 30, 2025, compared to $2.9 million as of December 2024

Discontinued operations:

* Net loss: $3.2 million for the quarter ended September 2025, compared to $2.4 million for the quarter ended September 2024

* Current assets: $11.4 million as of September 2025, compared to $25.3 million as of December 2024

**Year to Date Financial Results<sup>1</sup>**

Continuing Operations:

* Research and development (R&D) expenses were $2.9 million for the nine months ended September 30, 2025 compared to $2.2 million for the nine months ended September 30, 2024. The $0.7 million increase was primarily due to higher drug manufacturing expenses, higher professional service expenses in regulatory affairs, and higher volume of Plinabulin combination therapy research to support strategic business development and partnership initiatives.

* General and administrative (G&A) expenses were $3.4 million for the nine months ended September 30, 2025, compared to $4.9 million for the nine months ended September 30, 2024. The $1.5 million decrease was primarily due to lower salary expenses resulting from decrease in administrative headcount, lower professional services in consulting for business development and partnership initiatives, and lower company overhead expenses mainly due to decrease in investor relations services and D&O insurance related costs.

* Net loss: $6.2 million for the nine months ended September 2025, compared to $6.9 million for the nine months ended September 2024

Discontinued operations:

* Net loss: $2.2 million for the nine months ended September 2025, compared to $5.0 million for the nine months ended September 2024

**Note 1: Accounting Update**

Following definitive agreements in January 2025 to sell the majority of its Series A-1 Preferred Shares in SEED Therapeutics, BeyondSpring now reports SEED's financial results as discontinued operations under ASC 205-20. BeyondSpring currently owns approximately 38% of SEED and upon completion of the future sale transactions BeyondSpring would own approximately 14% of SEED's outstanding shares.

**About BeyondSpring**

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin's novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at beyondspringpharma.com.

**About SEED Therapeutics**

SEED Therapeutics is a clinical-stage biotechnology company pioneering rationally designed molecular glue degraders to treat diseases driven by undruggable proteins. Its proprietary **RITE3™** platform enables targeted protein degradation with small-molecule precision. SEED's lead candidate, **ST-01156**, is a brain-penetrant RBM39 degrader entering clinical development for Ewing sarcoma and other RBM39-dependent cancers. SEED's investors and collaborators include Eli Lilly and Eisai, both of whom have been instrumental in supporting SEED's mission to unlock undruggable disease targets. The company's pipeline includes nine programs across oncology, neurodegeneration, immunology, and virology. Learn more at seedtherapeutics.com.

**Cautionary Note Regarding Forward-Looking Statements**

This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet the Company's expectations regarding the potential safety, the ultimate efficacy or clinical utility of the Company's product candidates, increased competition in the market, the Company's ability to meet Nasdaq's continued listing requirements, and other risks described in BeyondSpring's most recent Form 10-K on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

**Contacts**

Investor Relations: ir@beyondspring.com

Media: pr@beyondspringpharma.com

---

| | | |
|:---|:---|:---|
| **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED BALANCE SHEETS**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED BALANCE SHEETS**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED BALANCE SHEETS**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)** |
|  | **As of** | **As of** |
|  | **December 31, 2024** | **September 30, 2025** |
|  |  | (Unaudited) |
| **Assets** |  |  |
| **Current assets:** |  |  |
| Cash and cash equivalents |  |  |
| Short term investments |  |  |
| Advances to suppliers |  |  |
| Prepaid expenses and other current assets |  |  |
| Current assets of discontinued operations |  |  |
| Total current assets |  |  |
| **Noncurrent assets:** |  |  |
| Property and equipment, net |  |  |
| Operating right-of-use assets |  |  |
| Other noncurrent assets |  |  |
| Noncurrent assets of discontinued operations |  |  |
| Total noncurrent assets |  |  |
| **Total assets** |  |  |
| **Liabilities and equity** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable |  |  |
| Accrued expenses |  |  |
| Current portion of operating lease liabilities |  |  |
| Other current liabilities |  |  |
| Current liabilities of discontinued operations |  |  |
| Total current liabilities |  |  |
| **Noncurrent liabilities:** |  |  |
| Operating lease liabilities |  |  |
| Deferred revenue |  |  |
| Other noncurrent liabilities |  |  |
| Noncurrent liabilities of discontinued operations |  |  |
| Total noncurrent liabilities |  |  |
| **Total liabilities** |  |  |
| **Commitments and contingencies** |  |  |
| **Shareholders**' **deficit** |  |  |
| Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 40,316,320 and 40,322,320 shares issued and outstanding as of December 31, 2024 and September 30, 2025, respectively) |  |  |
| Additional paid-in capital |  |  |
| Accumulated deficit |  |  |
| Accumulated other comprehensive income |  |  |
| Total BeyondSpring Inc.'s shareholders' deficit |  |  |
| Noncontrolling interests |  |  |
| Total shareholders' deficit |  |  |
| **Total liabilities and shareholders**' **deficit** |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)**<br>**(Unaudited)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)**<br>**(Unaudited)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)**<br>**(Unaudited)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)**<br>**(Unaudited)** | **BEYONDSPRING INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**<br>**(Amounts in thousands of U.S. Dollars (**"**$**"**), except for number of shares and per share data)**<br>**(Unaudited)** |
|  | **Three months ended** <br>**September 30,** | **Three months ended** <br>**September 30,** | **Nine months ended** <br>**September 30,** | **Nine months ended** <br>**September 30,** |
|  | **2024** | **2025** | **2024** | **2025** |
| **Revenue** |  |  |  |  |
| **Operating expenses** |  |  |  |  |
| Research and development |  |  |  |  |
| General and administrative |  |  |  |  |
| **Loss from operations** |  |  |  |  |
| Foreign exchange gain, net |  |  |  |  |
| Interest income |  |  |  |  |
| Other income, net |  |  |  |  |
| **Loss before income tax** |  |  |  |  |
| Income tax expenses |  |  |  |  |
| **Net loss from continuing operations** |  |  |  |  |
| **Discontinued operations** |  |  |  |  |
| &nbsp;&nbsp;Loss from discontinued operations |  |  |  |  |
| &nbsp;&nbsp;Gain on sale of subsidiary interests |  |  |  |  |
| &nbsp;&nbsp;Income tax expenses |  |  |  |  |
| **Net loss from discontinued operations** |  |  |  |  |
| **Net loss** |  |  |  |  |
| Less: Net income (loss) attributable to noncontrolling interests from continuing operations |  |  |  |  |
| Less: Net loss attributable to noncontrolling interests from discontinued operations |  |  |  |  |
| **Net income (loss) attributable to BeyondSpring Inc.** |  |  |  |  |
| **Earnings (loss) per share, basic and diluted** |  |  |  |  |
| &nbsp;&nbsp;Continuing operations |  |  |  |  |
| &nbsp;&nbsp;Discontinued operations |  |  |  |  |
| Basic and diluted earnings (loss) per share |  |  |  |  |
| Weighted-average shares outstanding |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted |  |  |  |  |
| **Other comprehensive loss, net of tax of nil:** |  |  |  |  |
| Foreign currency translation adjustment loss from continuing operations |  |  |  |  |
| Foreign currency translation adjustment gain (loss) from discontinued operations |  |  |  |  |
| **Comprehensive loss** |  |  |  |  |
| Less: Comprehensive loss attributable to noncontrolling interests from continuing operations |  |  |  |  |
| Less: Comprehensive loss attributable to noncontrolling interests from discontinued operations |  |  |  |  |
| **Comprehensive income (loss) attributable to BeyondSpring Inc.** |  |  |  |  |

---